Trend Analysis Report: Berry Plastics Group Inc (NYSE:BERY), Marinus Pharmaceuticals Inc (NASDAQ:MRNS), Total SA (ADR)(NYSE:TOT)

On Friday, Shares of Berry Plastics Group Inc (NYSE:BERY), subtract -0.90% and closed at $43.85 in the last trading session. The last trading range of the stock ranges between $43.47 and $44.56. Recently, the Board of Directors of Berry Plastics Group, Inc. (BERY) declared that Thomas E. (Tom) Salmon has been unanimously elected as Berry’s President and Chief Operating Officer effective October 3, 2016. As President and Chief Operating Officer, Salmon will be responsible for the Company’s operating businesses, operations, supply chain, and procurement. Salmon presently serves as President of the Company’s Consumer Packaging Division.

The Company also declared that its Chairman and Chief Executive Officer, Jonathan D. (Jon) Rich, has informed the Board of Directors of his intention to retire as Chief Executive Officer effective in February 2017. Upon his retirement, Rich will continue to serve as Executive Chairman of the Board.

“The creation of the President and Chief Operating Officer role is the next step in our ongoing succession process. Tom’s background, experience and track record of success leading multiple Berry divisions throughout his career with the Company make him eminently qualified to take on this important leadership role,” said Rich. “Berry is well positioned to continue the success we have achieved since our IPO in 2012. The Company has a strong leadership team and the time is right for the next generation to take Berry into the future. I look forward to continuing my role with the Company as Executive Chairman.”

Salmon, age 53, joined the Company in 2007 with Berry’s acquisition of Covalence Specialty Materials where he had led the Adhesives Division for four years. From 2007-14, he served as President of Berry’s Engineered Materials Division, before being designated President of Berry’s Rigid Closed Top Division in 2014 and President of Berry’s Consumer Packaging Division in 2015. Before joining Covalence, Salmon was General Manager of Honeywell Plastics and Global Sales Director for Allied Signal’s Engineering Plastics and Films. He began his career with General Electric and held various commercial positions during his 12 years in GE’s Plastics and Lighting divisions.

Marinus Pharmaceuticals Inc (NASDAQ:MRNS), subtract -9.00% and closed at $1.82 in the last trading session. The last trading range of the stock ranges between $1.75 and $2.00. The company’s Market capitalization is $32.31 Billion with the total Outstanding Shares of 19.51 million. Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, recently declared top-line results from a Phase 2 exploratory open-label clinical trial evaluating ganaxolone, its CNS-selective GABAA modulator, in females with PCDH19 pediatric epilepsy. In the trial, ganaxolone reduced seizure frequency from baseline in the majority of patients enrolled in the study and was generally safe and well tolerated. PCDH19 pediatric epilepsy is a rare, serious epilepsy characterized by early-onset cluster seizures, cognitive and sensory impairment, and behavioral disturbances, with no approved treatments. In 2015, the U.S. Food and Drug Administration granted Orphan Drug Designation to ganaxolone for the treatment of PCDH19.

Top-Line Results:

64% (7 of 11) of patients showed a seizure reduction contrast to baseline.

57% (4 of the 7 patients) showed a reduction of greater than 50% contrast to baseline.

57% (4 of the 7 patients) showed a reduction of greater than 50% contrast to baseline.

73% (8 of 11) of patients showed a boost in seizure-free days.

73% (8 of 11) of patients showed CGI-I (Clinical Global Impression of Improvement) scores of very much improved, much improved or minimally improved at their last visit when administered by the parent/caregiver, which correlated with overall seizure reduction and participation in the study extension.

Consistent with earlier studies, ganaxolone was generally safe and well tolerated. The most common drug-related adverse event was somnolence.

Michael G. Chez, M.D., a pediatric neurologist at Sutter Medical Center in Sacramento, California, and an investigator in the Phase 2 trial, commented, “The benefit that ganaxolone offered in reducing seizures is clinically meaningful for these difficult-to-treat patients with a severe, rare epilepsy. Children with PCDH19 epilepsy are faced with many comorbidities that impact the quality of life for them and their families. In addition to seizure reduction, the patients that I treated with ganaxolone displayed improved behavior and cognitive skills during treatment. A drug that can lessen seizure burden and behavioral comorbidities caused by this disease would be welcomed by patients, their families and the medical community.”

Total SA (ADR)(NYSE:TOT), jumped 0.13% and closed at $47.70 in the last trading session. The last trading range of the stock ranges between $47.09 and $47.83. During the 52-week trading session the minimum price at which share price traded, registered at $39.05 and reached to max level of $52.34. TOTAL S.A. operates as an integrated oil and gas company worldwide. The company operates through three segments: Upstream, Refining & Chemicals, and Marketing & Services. The Upstream segment engages in the exploration and production activities in about 50 countries, and produces oil or gas in about 30 countries; gas activities, counting purchase, sale, and shipping of liquefied natural gas (LNG); and trading of liquefied petroleum gas (LPG) and pet coke. This segment is also involved in the storage and transportation of natural gas; and generation and trading of power. The Refining & Chemicals segment provides petrochemicals, counting olefins and aromatics; polymer derivatives, such as polyethylene, polypropylene, polystyrene, and hydrocarbon resins; and specialty chemicals comprising elastomer processing and electroplating chemistry for automotive, construction, electronics, aerospace, and convenience goods markets. It is also involved in trading and shipping crude oil and petroleum products. The Marketing & Services segment supplies and markets petroleum products, counting aviation fuel, special fluids, LPG, bitumen, heavy fuels, and marine bunkers. It operates about 16,000 service stations. TOTAL S.A. also develops renewable energies with a focus on solar and biomass.

Leave a Reply

Your email address will not be published. Required fields are marked *